Survodutide, Formerly BI 456906, Impresses in Phase 2 Dose-F

Data from a phase 2 dose-finding trial from ADA 2023 suggests use of survodutide was associated with a mean body weight reduction of 14.9% at 46 weeks, with 67% of people using survodutide 4.8 mg losing 15% or more of their baseline body weight.

Related Keywords

Dublin , Ireland , United States , American , Zealand Pharma , Carel Le Roux , Carinne Brouillon , University College , Scientific Sessions Of The American Diabetes Association , Boehringer Ingelheim , Scientific Sessions , American Diabetes Association , Human Pharma , Dose Finding Study , American Diabetes , Zealand Pharma Phase ,